Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 9;27(1):864–875. doi: 10.1080/10717544.2020.1775724

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — (A) Assessment of the hemolytic effect of magnetite nanoparticles, PEGylated nanoparticles, and OmpA/PEGylated nanoparticles. Hemolysis assay shows an average hemolytic effect below 1% in all cases. (B) Platelet aggregation tendency of magnetite nanoparticles, PEGylated nanoparticles, and OmpA/PEGylated nanoparticles. Results show that there is no significant increase in the platelet aggregation of the different treatments compared to the negative control, PBS (1X). Cytotoxicity effects of OmpA/PEGylated nanoparticles after 1 (C) and 2 days (D). For all the tested concentrations, the observed viability levels were always above 90%, thereby indicating that the co-immobilization of OmpA has no significant impact on the high biocompatibility of the PEGylated nanoparticles.